Oftentimes, investing in early-stage biotech companies can mean seeing a few of your picks lose 95% or even 100% of their value. Drug development is highly risky since it involves creating something new.

But a few players focus on providing drugmakers with the services they need to discover or manufacture their medicines rather than doing the research and development (R&D) themselves.

Let's take a peek at two biotechs that make their money by solving the problems of other biopharma companies. Both have a solid chance of being lucrative purchases for investors with a bit of patience.

Continue reading

Source Fool.com